The Making of Max Planck

The Making of Max Planck By Elie DolginIn 1945, the Kaiser Wilhelm Society, Germany's premier science research institution, was in tatters. It was even at risk of being axed after the Second World War, but leading German scientists convinced the allies to rebuild and rebrand the renowned research organization. So an 86- year-old Max Planck once again assumed the presidency, after the Nazi regime forced him from the post in 1937. As part of the society's makeover, Planck, the

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

By Elie Dolgin

In 1945, the Kaiser Wilhelm Society, Germany's premier science research institution, was in tatters. It was even at risk of being axed after the Second World War, but leading German scientists convinced the allies to rebuild and rebrand the renowned research organization. So an 86- year-old Max Planck once again assumed the presidency, after the Nazi regime forced him from the post in 1937. As part of the society's makeover, Planck, the founder of quantum theory, offered his own name. In 1946, he served as the first honorary president of the Max Planck Society (MPS) during its early development in postwar Germany's British zone.

Planck, however, passed away less than a year before the society's first official meeting in February 1948 in Göttingen. At that time, his eponymous society comprised only 25 small institutes with a combined budget of around $5-6 million (about $50 million in today's ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Elie Dolgin

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo